QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Brem, S. Search for Related Content PubMed PubMed Citation

Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma

Department of Interdisciplinary Oncology and Neurosurgery, University of South Florida College of Medicine and Neuro-Oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL 33620 (S.B.); Department of Neuro-Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 (S.A.G., K.A.C., J.D.F.); Department of Neurosurgery, Baylor College of Medicine, Houston, TX 77030 (P.N.); Department of Hematology-Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322 (S.P.); Department of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA (J.B.A.); Department of Neurosurgery, Henry Ford Health System, Detroit, MI 48202 (T.M.); USA

³ Address correspondence to Steven Brem, c/o the NABTT CNS Consortium, 1650 Orleans St., Room G-93, Baltimore, MD 21231, USA (brem{at}moffitt.usf.edu).

Abstract

Penicillamine is an oral agent used to treat intracerebral copper overload in Wilson's disease. Copper is a known regulator of angiogenesis; copper reduction inhibits experimental glioma growth and invasiveness. This study examined the feasibility, safety, and efficacy of creating a copper deficiency in human glioblastoma multiforme. Forty eligible patients with newly diagnosed glioblastoma multiforme began radiation therapy (6000 cGy in 30 fractions) in conjunction with a low-copper diet and escalating doses of penicillamine. Serum copper was measured at baseline and monthly. The primary end point of this study was overall survival compared to historical controls within the NABTT CNS Consortium database. The 25 males and 15 females who were enrolled had a median age of 54 years and a median Karnofsky performance status of 90. Surgical resection was performed in 83% of these patients. Normal serum copper levels at baseline (median, 130 µg/dl; range, 50-227 µg/dl) fell to the target range of <50 µg/dl (median, 42 µg/dl; range, 12-118 µg/dl) after two months. Penicillamine-induced hypocupremia was well tolerated for months. Drug-related myelosuppression, elevated liver function tests, and skin rash rapidly reversed with copper repletion. Median survival was 11.3 months, and progression-free survival was 7.1 months. Achievement of hypocupremia did not significantly increase survival. Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme.

This article has been cited by other articles:

				Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski, and D. R. Richardson Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond Clin. Cancer Res., December 1, 2006; 12(23): 6876 - 6883. [Abstract] [Full Text] [PDF]

				P. O. Sakariassen, L. Prestegarden, J. Wang, K.-O. Skaftnesmo, R. Mahesparan, C. Molthoff, P. Sminia, E. Sundlisaeter, A. Misra, B. B. Tysnes, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells PNAS, October 31, 2006; 103(44): 16466 - 16471. [Abstract] [Full Text] [PDF]